A securities class action has been filed against Telix Pharmaceuticals Ltd. (TLX) on behalf of persons or entities who purchased or otherwise acquired publicly traded Telix securities between February 21, 2025 through August 28, 2025. This case has been filed in the USDC – SDIN.
On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.”
On this news, Telix’s American Depositary Share (“ADS”) price fell 10.44% on July 23, 2025.